Few treatments for obesity exist and, whereas efficacious therapeutics for hyperlipidemia are available, further improvements are desirable. Thyroid hormone receptors (TRs) regulate both body weight and cholesterol levels. However, thyroid hormones also have deleterious effects, particularly on the heart. The TR␤ subtype is involved in cholesterol lowering and possibly elevating metabolic rate, whereas TR␣ appears to be more important for control of heart rate (HR). In the current studies, we examined the effect of TR␤ activation on metabolic rate and HR with either TR␣1 ؊͞؊ mice or the selective TR␤ agonist KB-141 in mice, rats, and monkeys. 3,5,3-triiodi-L-thyronine (T3) had a greater effect on increasing HR in WT than in TR␣ ؊͞؊ mice (ED15 values of 34 and 469 nmol͞kg͞day, respectively). T 3 increased metabolic rate [whole body oxygen consumption (MV O 2 )] in both WT and TR␣ ؊͞؊ mice, but the effect in the TR␣ 1 ؊͞؊ mice at the highest dose was half that of the WT mice. Thus, stimulation of MV O 2 is likely due to both TR␣ and -␤. T3 had equivalent potency for cholesterol reduction in WT and TR␣ ؊͞؊ mice. KB-141 increased MVO 2 with selectivities of 16.5-and 11.2-fold vs. HR in WT and TR␣ 1 ؊͞؊ mice, respectively. KB-141 also increased MV O 2 with a 10-fold selectivity and lowered cholesterol with a 27-fold selectivity vs. HR in rats. In primates, KB-141 caused significant cholesterol, lipoprotein (a), and body-weight reduction (up to 7% after 1 wk) with no effect on HR. TR␤-selective agonists may constitute a previously uncharacterized class of drugs to treat obesity, hypercholesterolemia, and elevated lipoprotein (a). O besity and atherosclerosis are important medical problems with major impact on morbidity and mortality. Current treatments for obesity have shown limited efficacy and safety; therefore, there is a need for improved therapies (1). A major risk factor for atherosclerosis is low-density lipoprotein (LDL) cholesterol. Although there are excellent treatments for elevated LDL cholesterol, therapeutic goals are commonly not met. As targets for lowering of cholesterol become more aggressive, there is a need for more modalities to meet these goals. Lipoprotein (a) [Lp(a)] is an important risk factor, elevated in many patients with premature atherosclerosis, and few therapies lower Lp(a) (2).
O besity and atherosclerosis are important medical problems with major impact on morbidity and mortality. Current treatments for obesity have shown limited efficacy and safety; therefore, there is a need for improved therapies (1) . A major risk factor for atherosclerosis is low-density lipoprotein (LDL) cholesterol. Although there are excellent treatments for elevated LDL cholesterol, therapeutic goals are commonly not met. As targets for lowering of cholesterol become more aggressive, there is a need for more modalities to meet these goals. Lipoprotein (a) [Lp(a)] is an important risk factor, elevated in many patients with premature atherosclerosis, and few therapies lower Lp(a) (2) .
Thyroid hormones reduce body weight, LDL cholesterol, and Lp(a); thus, exploitation of these properties may be useful for therapy (3) (4) (5) (6) . Unfortunately, endogenous thyroid hormones are nonselective and produce undesirable side effects, particularly cardiac stimulation (7, 8) . Development of thyromimetics devoid of cardiac effects could have therapeutic potential as antiobesity and lipid-lowering agents.
Thyroid hormone receptors (TRs) are divided into two primary subtypes (TR␣ and -␤), which are the products of two genes of the superfamily of nuclear hormone receptors (4, 7) . TRs mediate distinct physiologic effects due to differences in tissue abundance or receptor-specific activity (9) . Studies in patients with the syndrome of resistance to thyroid hormone, in which there are abnormal TR␤, and with TR␣ 1 Ϫ͞Ϫ mice suggest that TR␣ is the major TR regulating heart rate (HR) (4, (9) (10) (11) (12) . TR␤ is critical in controlling hepatic cholesterol metabolism and thyroid-stimulating hormone (TSH) suppression, which may be due to high expression of TR␤ in liver (70-80% of total TR) and pituitary (10, 12, 13) . The TR␤Ϫselective agonist GC-1 reduces plasma cholesterol levels with minimal cardiac effects in mice and rats; however, GC-1 also exhibits relatively decreased uptake into the heart compared with liver, and these differences, rather than TR␤ selectivity (14) , might account for its selective pharmacology. The effect of GC-1 on metabolic rate has not been reported; therefore, the potential of GC-1 or other TR␤-selective agonists as antiobesity compounds is unclear. Clinically useful TR␤ agonists would require high selectivity for cholesterol reduction with modest metabolic rate increases (5-10%) without tachycardia over a wide therapeutic dose range to be safe and efficacious.
The role of TR␤ in modulating metabolic rate is currently unclear. GC-1 up-regulates uncoupling protein 1 in brown adipose tissue (15) , whereas a study using TR␤ Ϫ͞Ϫ mice suggests no effect of TR␤ on body weight (16) . No studies have measured whole body metabolic rates by using either TR␣ 1 Ϫ͞Ϫ mice or TR␤-selective agents.
KB-141 is a TR agonist that binds to the human (h)TR␤ with a 14-fold higher affinity than to hTR␣ (17) . In the current studies, we used KB-141 to examine effects of selective activation of TR␤ in control and TR␣ Ϫ͞Ϫ mice, cholesterol-fed rats, and cynomolgus monkeys. The latter more closely resemble humans in terms of lipoprotein metabolism and regulation of body weight (18, 19) . 3,5,3Ј-Triiodi-L-thyronine (T 3 ), the major active form of thyroid hormone, increased the metabolic rate in both WT and TR␣ Ϫ͞Ϫ mice, but the increase for the WT animals was greater than with the TR␣ Ϫ͞Ϫ mice. These data imply that both TR␣ and -␤ regulate the metabolic rate. As compared with T 3 , KB-141 reduced plasma cholesterol levels selectively vs. increasing HR in all three models. Relative to T 3 , KB-141 also increased whole body oxygen consumption (MV O 2 ) in both mice and rats more than HR. In monkeys, KB-141 decreased body weight after 1 wk of treatment by up to 7% and Lp(a) by up to 56% without tachycardia. These studies suggest that selective stimulation of the TR␤ might be exploited as a therapeutically effective means to lower weight, plasma cholesterol, and Lp(a) without eliciting deleterious cardiac effects.
Abbreviations: TR, thyroid hormone receptors; hTR, human TR; HR, heart rate; LDL, lowdensity lipoprotein; TSH, thyroid-stimulating hormone; MVO 2 , whole body oxygen consumption; Lp(a), lipoprotein (a); T3, 3,5,3Ј-triiodi-L-thyronine; TRAF, thyroid hormone alkaline phosphatase.
Methods
Studies in TR␣1 ؊͞؊ Mice. Development of TR␣ 1 Ϫ͞Ϫ mice has been described (9-11). After 2 wk of cholesterol feeding (1.5% cholesterol, 0.5% cholic acid), WT or TR␣ 1 Ϫ͞Ϫ mice were treated orally with vehicle (10% m-pyrol, 5% ethanol, 5% cremaphor, and 80% water for all studies) or 1.54-462 nmol͞kg T 3 per day for 7 days (n ϭ 10 per group). Before and after 7 days of treatment, MV O 2 was determined in conscious mice by using Oxymax chambers (Columbus Instruments, Columbus, OH) (18, 19) . The mice were then anesthetized with i.p. sodium pentobarbital (30 mg͞kg), and HRs were measured by using lead II ECG. Afterward, blood samples were removed from the vena cava and analyzed for plasma HDL and LDL cholesterol and blood chemistries (liver enzymes, electrolytes, blood urea nitrogen, etc.), as described (14) . TSH could not be measured in mice because no reliable assay existed at the time these studies were performed. An identical study was done by using KB-141 (154-2,920 nmol͞kg per day), a TR␤-selective agonist that will be described below.
Previous studies on TR␣ Ϫ͞Ϫ mice from our laboratories were done in mice instrumented for conscious HR and body temperature measurements with telemetry (10) . To reproduce these conditions, animals were implanted with ECG and temperature leads and after recovery, the TR␣ 1 Ϫ͞Ϫ and WT mice were treated orally (after 2 wk of cholesterol feeding) with either vehicle or 154 nmol͞kg T 3 per day for 7 days (n ϭ 5 per group). Body temperatures and HR were monitored throughout the study with telemetry (Datasciences, St. Paul, MN) and at end of the study, MV O 2 was determined.
Studies with KB-141. TR-binding affinity studies and reporter cell assay.
TR-binding affinities were measured as described (20, 21) . Briefly, KB-141 ( Fig. 1) 1 (112 Ϯ 8 pM); therefore, the IC 50 for an unlabeled compound with equal affinity (K i ) for the two subtypes is lower for hTR␤ 1 than for hTR␣ 1 . The Cheng-Prusoff relationship for a competitive inhibitor was used to obtain the affinity (K i ) for binding to the hTRs (20) (21) (22) . Normalized hTR selectivity was calculated as IC 50 [(hTR␣ 1 )͞IC 50 (hTR␤ 1 
The KB-141 agonist profile was determined by using Chinese hamster ovary K1 cells stably transfected with expression vectors for hTR␣ 1 or -␤ 1 and subsequently with a reporter vector encoding a secreted form of alkaline phosphatase (23, 24) and containing a thyroid hormone response element. The cell lines thyroid hormone alkaline phosphatase (TRAF)-␣ and -␤ were exposed to serial dilutions of agonists and incubated for 48 h. Alkaline phosphatase in the cell culture media was then measured by using a chemiluminescent assay (24, 25) . Cholesterol-fed rat studies. Sprague-Dawley rats (250-300 g) were cholesterol-fed for 2 wk and were then dosed once daily with KB-141, T 3 (Sigma), or vehicle (n ϭ 5-6 per group) by oral gavage for 7 days. MV O 2 was then measured in conscious rats by using Oxymax chambers. Rats were then anesthetized with i.p. sodium pentobarbital (30 mg͞kg), and HR was measured by using lead II ECG. Blood was collected and analyzed for cholesterol, TSH, and blood chemistries as described (14) . The percent of total cholesterol composed of LDL was Ͼ90% after cholesterol feeding.
The relative tissue uptake of T 3 and KB-141 was determined. Rats were anesthetized with 30 mg͞kg pentobarbital, i.p., and either T 3 or KB-141 (10 mol͞kg) was injected into the right jugular vein (n ϭ 3 per group). Plasma and tissue samples were collected 1 h after treatment. Samples were weighed and homogenized with three volumes of deionized water, and tissue concentrations were determined by using liquid chromatography͞MS, as described (14) .
A separate group of rats was used for isolated heart studies to examine cardiac contractile function and hypertrophy (heart weight͞body weight). After 7 days of treatment with vehicle, T 3 , or KB-141 (1.54-2,920 mol͞kg per day, n ϭ 5 per group), hearts were removed and retrogradely perfused with Krebs-Henseleit buffer, and the left ventricles were fitted with a balloon for measurement of developed pressure and HR as described (26) . Studies in Cynomolgus Monkeys. Cynomolgus monkeys were dosed with KB-141 (154, 462, and 924 nmol͞kg per day) or T 3 (46.2 and 154 nmol͞kg per day) (n ϭ 5 per group) orally once daily for 7 days. At the end of this period, animals were anesthetized with ketamine (3-5 mg), and blood pressure and HR were determined by using a pressure cuff at the base of the tail. Blood samples were taken for analysis of cholesterol and blood chemistries. Dose-response studies with T 3 in TR␣ 1 Ϫ͞Ϫ and WT mice are shown in Fig. 3 . T 3 had reduced potency on HR in TR␣ 1 Ϫ͞Ϫ mice relative to WT (P Ͻ 0.05). MV O 2 was increased by T 3 in a dose-dependent manner in TR␣ 1 Ϫ͞Ϫ mice, but the increase was less than in WT mice (P Ͻ 0.05); however, the increase in MV O 2 was greater than that of HR (Fig. 3) . We assigned potency values as ED 50 for cholesterol (dose reducing cholesterol 50%), ED 15 for HR (dose increasing HR 15%, viewed as the highest acceptable increase), and ED 5 Ϫ͞Ϫ mice normalized for WT mice was 9.7-fold ( Table 1 ). The effects of T 3 on cholesterol are similar in TR␣ 1 Ϫ͞Ϫ animals relative to WT. This lowering is likely due to a decrease in LDL cholesterol, because Ͼ90% of the total plasma cholesterol in these animals is the LDL form (27) (28) (29) (30) (31) (32) . Thus, under these conditions, cholesterol lowering is primarily regulated by TR␤, MV O 2 by both TR␤ and -␣, and HR mostly by TR␣. KB-141 is a full agonist in both the TR␣ and -␤ reporter cell systems (Methods and Table 3 ). KB-141 is equipotent to T 3 in TRAF-␤ cells (EC 50 s of 3.5 and 3.4 nM for T 3 and KB-141, respectively), but KB-141 has 12% the potency of T 3 in TRAF-␣ cells (EC 50 s of 1.3 and 11.2 nM for T 3 and KB-141, respectively). Thus, the TR␤͞-␣ selectivity KB-141 normalized to that of T 3 is 8.3 (Table 3 ) . Effect of KB-141 in TR␣1 ؊͞؊ and WT Mice. KB-141 increased MV O 2 with selectivities of 16.5-and 11.2-fold vs. HR in WT and TR␣ 1 Ϫ͞Ϫ mice (Table 1) . Similar selectivities of 14.2-and 13.6-fold, respectively, were observed for cholesterol lowering vs. HR in both groups of animals ( Table 1) . KB-141 was less potent for all parameters compared with T 3 , which is consistent with its lower affinity for TR␤ than T 3 . Effect of KB-141 in cholesterol-fed rats. Dose-response effects of T 3 and KB-141 on HR, MV O 2 , and cholesterol lowering in cholesterol-fed rats are shown in Fig. 4 and Table 4 . Cholesterol was reduced in a dose-dependent manner by T 3 and KB-141 (primarily LDL-cholesterol reduction), with KB-141 being Ϸ30% as potent as T 3 (Table 4) , consistent with the lower TR␤-binding affinity for KB-141. HR was increased by T 3 and KB-141, although KB-141 was significantly less potent (Table 4) . Thus, KB-141 is Ϸ27-fold more selective for cholesterol lowering vs. tachycardia compared with T 3 . TSH was reduced by T 3 and KB-141 in parallel with cholesterol reduction, consistent with TR␤-dependent actions (Table 4) . MV O 2 was increased in a dose-dependent manner by T 3 and KB-141 (Fig. 4, Table 4 ), although the slope of the curve was significantly (P Ͻ 0.05) shallower for KB-141 based on the log curve fit. KB-141 has a 9-fold greater selectivity for MV O 2 changes compared with HR (potency ratio for ED 15 HR͞ED 5 MV O 2 , Table 4 ). Levels of T 3 and KB-141 were determined in samples from a separate group of rats. The tissue͞plasma ratios for heart were 1.0 and 0.7; for liver, 7.5 and 5.6; for adipose tissue, 0.2 and 0.3; and for skeletal muscle, 0.6 and 0.4 for T 3 and KB-141, respectively. T 3 and KB-141 appear to be similar in their abilities to penetrate these tissues, suggesting that the selectivity for cholesterol lowering (and possibly MV O 2 ) is due to TR␤ selectivity.
Results

Effect of T3 in Cholesterol-
Isolated Rat Heart Studies. Cholesterol-fed rats were treated with T 3 or KB-141 for 7 days, after which the hearts were removed and cardiac function ex vivo was determined. There were no differences in body weights among groups. HR changes in isolated perfused hearts mirrored drug effects in vivo such that KB-141 had a lower potency for producing tachycardia (ED 15 ϭ 31 vs. 2,893 nmol͞kg per day for T 3 and KB-141, respectively). KB-141 had no effect on inotropy (contractility) or lusitropy (rate of relaxation) nor did it cause cardiac hypertrophy, except at very high doses (shown as ratio of heart weight to body weight in Fig.  5 ). By contrast, T 3 caused a dose-dependent increase in heart weight͞body weight ratio (ED 15 ϭ 49 nmol͞kg per day), suggesting increased cardiac work. T 3 caused a significant and dose-dependent increase in inotropy (e.g., left ventricular developed pressure ϭ 121 Ϯ 4 mm Hg for vehicle and 153 Ϯ 4 mm Hg at 462 nmol͞kg T 3 per day). These results are consistent with the large increase in MV O 2 and direct cardiac effects of T 3 . Because these effects are not observed with KB-141, it is likely that the T 3 effects on heart weight and inotropy are mediated through TR␣.
Primate Studies. KB-141 was administered for 7 days to cynomolgus monkeys to determine effects in a model more closely resembling humans. Plasma cholesterol (Fig. 6 ) was reduced in a dose-dependent manner by KB-141 with a reduction of Ϸ35% at the highest dose, and most of this reduction was due to reduction in LDL cholesterol. Baseline LDL cholesterol was 49 Ϯ 2 mg͞dl, and HDL cholesterol was 43 Ϯ 2 mg͞dl. No tachycardia was observed. Despite the short duration of treatment, body weight was also significantly reduced by KB-141 by 5% at the 462 nmol͞kg per day dose and 7% at the 924 nmol͞kg per day dose compared with paired predrug weights (Fig. 5) . The animals were fed ad libitum; food consumption and blood chemistries were normal (blood urea nitrogen, creatinine, electrolytes, liver enzymes, creatine kinase, etc.), and the animals quickly regained their weight after withdrawal of treatment, suggesting that the animals were healthy. No effect of KB-141 on blood pressure was noted. T 3 at 46.2 and 154 nmol͞kg per day produced cholesterol lowering equivalent to 924 nmol͞kg per day KB-141 but with significant tachycardia. KB-141 significantly reduced Lp(a) by Ϸ50% at the 462-and 924-nmol͞kg per day doses (Fig. 6) , as did T 3 (data not shown).
Discussion
We addressed the potential for selectively stimulating TR␤ vs. -␣ for inducing weight loss and lowering plasma cholesterol and Lp(a) levels without excessively stimulating HR, by comparing T 3 with the TR␤-selective KB-141. We confirmed that KB-141 was TR␤-selective in both TR-binding and cell-based assays. We used three in vivo model systems: WT and TR␣ Ϫ͞Ϫ mice, cholesterol-fed rats, and cynomolgus monkeys. Each system offers distinct advantages, and results with the three systems were complementary. For mice and rats, we measured MV O 2 as an index of metabolic rate, which contributes to thyroid hormone-induced weight loss (4), and in primates we measured weight.
T 3 lowered cholesterol to a similar degree in WT and TR␣ 1 Ϫ͞Ϫ mice but showed differences in effects on MV O 2 and HR. Whereas T 3 induced a large increase in HR in WT mice, the increase was much less for the TR␣ 1 Ϫ͞Ϫ mice. T 3 increased significantly MV O 2 in both the WT and TR␣ 1 Ϫ͞Ϫ mice, although the maximal stimulation in the TR␣ 1 Ϫ͞Ϫ mice was Ϸ60% that observed in the WT mice. These data confirm previous results that TR␤ primarily regulates plasma cholesterol levels and TR␣ primarily regulates HR (9) (10) (11) 14) . They also suggest that both TR␣ and -␤ can regulate MV O 2 . In support of the notion that TR␤-selective stimulation might increase MV O 2 without increasing HR was the observation that in TR␣ Ϫ͞Ϫ mice, there is a 10-fold window in which MV O 2 could be therapeutically increased by T 3 without tachycardia, whereas T 3 showed no selectivity in WT mice (Fig. 3) .
In comparing the WT and TR␣ 1 Ϫ͞Ϫ mice, we surprisingly found that body temperature can be dissociated from MV O 2 . As shown previously (10, 11) , TR␣ 1 Ϫ͞Ϫ mice display lower body temperatures than WT mice, but these TR␣ 1 Ϫ͞Ϫ mice paradoxically have slightly but significantly higher metabolic rates than WT (Fig. 2) . Further, whereas T 3 treatment increased MV O 2 in both WT and TR␣ 1 Ϫ͞Ϫ mice, it did not change body temperature. We do not understand why this dissociation occurs; it is conceivable that the set point for body temperature is altered in TR␣ 1 Ϫ͞Ϫ mice. As expected, KB-141 showed similar selectivities for cholesterol and MV O 2 in both WT and TR␣ 1 Ϫ͞Ϫ mice. Compared with T 3 , KB-141 exhibited selective stimulation of MV O 2 and reduction of plasma cholesterol levels relative to HR in cholesterol-fed rats. KB-141 was 27-fold more selective for cholesterol lowering (ED 50 ) vs. tachycardia than T 3 and 9-fold more selective for the MV O 2 response. The greater selectivity of KB-141 for cholesterol lowering vs. effects on MV O 2 suggests that both TR␣ and -␤ mediate the latter effect.
We also examined effects of T 3 and KB-141 on hearts isolated from control and treated animals. Rodent ventricles contain TR␤ receptors (33, 34) and therefore might respond to a TR␤ agonist. However, KB-141 had no effect on contractility or rate of relaxation. Whereas T 3 induced cardiac hypertrophy, this was not observed for KB-141. Therefore modest degrees of metabolic rate increases can be seen without cardiac side effects.
TSH was suppressed by KB-141 in rats and this mirrored cholesterol-lowering. These observations are consistent with TR␤-selective activation being critical for both effects (4). They also imply that in a therapeutic setting, use of a compound like KB-141 would suppress plasma and tissue levels of T 3 and T 4 . Whereas the administered ligand in this example would compensate for the endogenous hormones in terms of TR␤ stimulation, it may not appreciably activate TR␣, which could therefore cause a relative TR␣ hypothyroidism; future work may address this.
Actions of one compound previously reported to cause selective TR modulation might be explained in part by selective tissue uptake. GC-1 has selective effects on cholesterol vs. HR in rodents but is not as readily taken up by the rat heart relative to the liver as compared with T 3 (14) . The thyromimetic, CGS-23425, reduces cholesterol with no thermogenic or HR effects, although the mechanism for this separation is unclear (23) . The selectivity for cholesterol lowering vs. tachycardia for SKF-94901 can be partially explained by selective tissue uptake (14, 35) . The distribution of KB-141 relative to plasma was equivalent to T 3 in heart, liver, muscle, and adipose tissue. Therefore the selectivity for lowering of cholesterol and MV O 2 is likely due to the TR␤ selectivity of KB-141.
KB-141 was also examined in cynomolgus monkeys that have a lipoprotein profile resembling humans (primarily LDL cholesterol) more closely than rodents. Plasma cholesterol was reduced in a dose-dependent manner by KB-141 with a reduction of Ϸ35% at the highest dose. No tachycardia was observed, showing selectivity for cholesterol lowering for KB-141, unlike T 3 . In the monkeys, KB-141 also lowered Lp(a) levels by 50%. Lp(a) has been suggested previously as a target for nonselective thyroid agonists (6) . Thus these atherogenic particles may be regulated by TR␤, and this class of thyromimetics may deserve further exploration as a regulator of Lp(a), for which current therapies have limited efficacy.
Monkeys are also a better model than rodents for examining effects on weight loss, because the animals are not growing. Body weight was significantly reduced by KB-141 by 5% at the 462 nmol͞kg per day dose and 7% at the 924 nmol͞kg per day dose compared with paired predrug weights, most likely due to increased MV O 2 . Muscle loss and frank myopathy can be observed in hyperthyroidism (4), but the KB-141-treated animals appeared healthy and maintained their pretreatment level of Effect of KB-141 on HR, cholesterol body weight, and Lp(a) in cynomolgus monkeys after 7 days of treatment (46.2, 154 nmol͞kg T 3 per day ϭ 25%, 24% incr. HR, respectively).
food consumption, and body chemistries (electrolytes, renal function indices, blood urea nitrogen, and liver functions) remained normal. Thus, it is unlikely that the weight loss was due to a toxic effect of KB-141. Interestingly, little TR␤ mRNA is reported in skeletal muscle in humans (4) .
In summary, our results in three species show that a separation between potential beneficial vs. deleterious effects of TR stimulation is possible. These effects include reductions of plasma cholesterol and Lp(a) and weight. It is likely in all three cases that the separation is due to the ability of KB-141 to selectively activate TR␤ vs. -␣. Thus, selective thyromimetics may offer several types of therapeutic potential and are candidates for further exploration.
